ACCESSIBILITY

24/7

Headlines

13:53

The breach that doesn’t have to happen - and what real cyber warfare looks like

13:42

"We are able to understand what drives cancer. This changes the entire course of the disease"

12:19

Why Disney is licensing AI instead of fighting it

11:53

Israeli healthtech faces a more selective funding market after the war

Buzz

Most popular

Daily

Weekly

Palo Alto Networks CEO: “We’re happy Wiz is now part of Google, it gives us more room to operate”

UAE reportedly behind Elbit’s record $2.3 billion defense deal

Cyera raises $400 million at $9 billion valuation in Blackstone-led round

Vega raises $120 million Series B as two-year-old cyber startup hits $700 million valuation

Dell acquires AI data-infrastructure startup Dataloop in $120 million all-cash deal

More news

Teva

20 stories about Teva

Teva Canada Probed by Ontario Government

23.10.17|Lilach Baumer

According to a report by Canadian newspaper Toronto Star the company is under investigation for alleged illegal rebates given to pharmacies to boost sales. A Teva spokesman said the company will cooperate fully with any investigation by the Ontario Ministry of Health.

Teva Submits Potential Moneymaker Migraine Drug for FDA Approval

18.10.17|Dror Reich and Lilach Baumer

Teva’s patent for its moneymaker multiple sclerosis drug Copaxone expired last year

New Teva CEO Kåre Schultz to Relocate to Israel

17.10.17|Golan Hazani

Mr. Schultz, who led Copenhagen-based H. Lundbeck A/S since 2015, will come to Israel and assume his new position by the end of the month

Teva’s Stock Drops After Approval of Copaxone Competitors

08.10.17|Lilach Baumer

A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug

Teva Loses Copaxone Market Exclusivity

04.10.17|Lilach Baumer

Rival Mylan received FDA approval for its generic versions of Copaxone, Teva’s flagship drug

Teva Sells Remaining Women's Health Assets

18.09.17|Lilach Baumer

After selling its Paragard business for $1.1 billion last week, Teva's remaining Women's Health business will be split between CVC Capital Partners and Foundation Consumer Healthcare in a $1.38 billion cash deal

Teva Negotiating Sale of Remaining Women's Health Assets, Report Says

14.09.17|Lilach Baumer

CVC Capital Partners is nearing a $800 million deal for Teva's remaining Women's Health business, Bloomberg reported Thursday

The Ten Challenges Facing Teva's New CEO

12.09.17|Sophie Shulman

Kåre Schultz is the right man for the job, but he's facing multiple problems, from a changing market to a problematic board

Teva Sells IUD Business for $1.1 Billion

12.09.17|Lilach Baumer

Going forward, the company will focus on central nervous system and respiratory treatments, shedding its Women's Health and Oncology and Pain businesses

New CEO to Break Teva’s Copaxone Habit

11.09.17|Sophie Shulman, Dror Reich

Troubled drugmaker says new CEO must work to quickly regain its financial credibility

Teva Appoints Lundbeck's Schultz as CEO

11.09.17|Dror Reich and Micky Grunfeld

The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated

Bidders Line Up for Teva’s Women Health Unit, Report Says

23.08.17|Dror Reich

Church & Dwight Co. and Cooper Companies Inc. join other bidders for troubled drugmaker assets, Bloomberg reported Tuesday

U.S. Congress to Investigate Rising Multiple Sclerosis Drug Prices

21.08.17|Dror Reich

Two Congressmen are looking into the rising MS drug prices of seven pharmaceutical companies

Cerberus, Advent Eye Teva's European Assets, Report Says

15.08.17|Calcalist

The private equity firms are taking an interest in Teva's European oncology and pain treatment assets, estimated at $700 million to 1$ billion, according to a Bloomberg report

Allergan Sketches Road Show to Sell Teva Stake

14.08.17|Golan Hazani

The company is in discussions with investment bankers and brokers to sell its Teva shares, said one person familiar with the matter

With Bloated Debt, Teva Looks to Sell Assets

10.08.17|Eli Shimony and Gil Kalian

The generic drugmaker said it is looking to sell Medis, an Iceland-based company it bought in 2016

Teva’s Perfect Storm Sends Tel-Aviv Stock Exchange Down

06.08.17|Calcalist

Teva’s stock price dropped sharply on Thursday and Friday after the company released quarterly revenue and profits that fell short of analysts’ forecasts

מנכ"ל AstraZeneca פסקל סוריו Pascal Soriot

Soriot's Teva Appointment Unlikely, Says Activist Investor

06.08.17|Golan Hazani

Teva’s board was surprised to learn AstraZeneca's CEO Pascal Soriot will not be joining the company. Teva activist investor Benny Landa called an early report on Teva's negotiations with Mr. Soriot "devastating"

Allergan Can Now Sell 9.8% Teva Stake

03.08.17|Dror Reich

Yesterday, a lock-up period on $3.2 billion worth Teva Pharmaceutical Industries’ shares owned by Allergan ended

Teva in Talks to Appoint AstraZenca's Pascal Soriot as CEO

18.07.17|Golan Hazani

Mr. Soriot has met with the company’s search committee and its chairman and expressed his agreement to serve as its next CEO, people familiar with the matter said